Cost-effectiveness analysis of immediate radical cystectomy versus intravesical Bacillus Calmette-Guerin therapy for high-risk, high-grade (T1G3) bladder cancer

Cancer

Volumn 115, Issue 23, 2009, Pages 5450-5459

  Kulkarni, Girish S ^a,b   Alibhai, Shabbir M H ^a,b,c   Finelli, Antonio ^a,b   Fleshner, Neil E ^a   Jewett, Michael A S ^a   Lopushinsky, Steven R ^b   Bayoumi, Ahmed M ^b,c,d  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Bladder cancer; Cost; Cost effectiveness; Cystectomy; Economic analysis; Intravesical immunotherapy

Indexed keywords

BCG VACCINE;

ADULT; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER PATIENT; CANCER RISK; CASE REPORT; COHORT ANALYSIS; COMORBIDITY; CONSERVATIVE TREATMENT; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; CYSTECTOMY; HEALTH CARE SYSTEM; HUMAN; INTERMETHOD COMPARISON; MALE; MEDICAL DECISION MAKING; MONTE CARLO METHOD; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; SIMULATION; TREATMENT OUTCOME;

BCG VACCINE; COMORBIDITY; COST-BENEFIT ANALYSIS; CYSTECTOMY; HUMANS; MALE; MARKOV CHAINS; MIDDLE AGED; PROBABILITY; PROGNOSIS; QUALITY-ADJUSTED LIFE YEARS; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; URINARY BLADDER NEOPLASMS;

EID: 72249085781     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24634     Document Type: Article

References (51)

1. Canadian Cancer Society/National Cancer Institute of Canada. Canadian Cancer Statistics 2007. Toronto, Ontario, Canada: Canadian Cancer Society, National Cancer Institute of Canada; 2007. Available at: http://www.ncic. cancer.ca Accessed December 17, 2007.
2. American Cancer Society. Cancer Facts and Figures 2005. Atlanta, Ga: American Cancer Society; 2005. Available at: http://www.cancer.org/2006 Accessed on August 6, 2006.
3. Humphrey PA. Urinary bladder pathology 2004: an update. Ann Diagn Pathol. 2004;8:380-389.
4. Avritscher EB, Cooksley CD, Grossman HB, et al. Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology. 2006;68:549-553.
5. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics. 2003;21:1315-1330. (Pubitemid 38041357)
6. Manoharan M, Soloway MS. Optimal management of the T1G3 bladder cancer. Urol Clin North Am. 2005;32:133-145. (Pubitemid 40613040)
7. Malavaud B. T1G3 bladder tumours: the case for radical cystectomy. Eur Urol. 2004;45:406-410. (Pubitemid 38376195)
8. Turner W. T1G3 bladder tumours: the case for conservative treatment. Eur Urol. 2004;45:401-405. (Pubitemid 38376194)
9. Kulkarni GS, Finelli A, Fleshner NE, Jewett MA, Lopushinsky SR, Alibhai SM. Optimal management of high-risk T1G3 bladder cancer: a decision analysis [serial online]. PLoS Med.2007;4:e284.
10. Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on cost-effectiveness in health and medicine. JAMA. 1996;276:1339-1341.
11. Naimark D, Krahn MD, Naglie G, Redelmeier DA, Detsky AS. Primer on medical decision analysis: part 5-working with Markov processes. Med Decis Making. 1997;17:152-159. (Pubitemid 27157030)
12. Juffs HG, Moore MJ, Tannock IF. The role of systemic chemotherapy in the management of muscle-invasive bladder cancer. Lancet Oncol. 2002;3:738-747. (Pubitemid 35446743)
13. Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance Bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study. J Urol. 2000;163:1124-1129.
14. Statistics Canada. Life Tables, Canada, Provinces and Territories 1995-1997. Statistics Canada Catalogue no. 84- 537-XIE. Ottawa, Ontario Canada: Minister of Industry; 2002. Available at: http://www.statcan.gc.ca/pub/84-537-x/ 4064441-eng.htm Accessed on December 12, 2005.
15. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18:3068-3077.
16. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19:666-675. (Pubitemid 32120143)
17. Cookson MS, Herr HW, Zhang ZF, Soloway S, Sogani PC, Fair WR. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol. 1997;158:62-67. (Pubitemid 27251595)
18. Shahin O, Thalmann GN, Rentsch C, Mazzucchelli L, Studer UE. A retrospective analysis of 153 patients treated with or without intravesical Bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J Urol.2003;169:96-100; discussion 100.
19. Stockle M, Alken P, Engelmann U, Jacobi GH, Riedmiller H, Hohenfellner R. Radical cystectomy-often too late? Eur Urol.1987;13:361-367.
20. Herr HW, Sogani PC. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol.2001;166:1296-1299. (Pubitemid 32862159)
21. Herr HW, Schwalb DM, Zhang ZF, et al. Intravesical Bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: 10-year followup of a prospective randomized trial. J Clin Oncol. 1995;13:1404-1408.
22. Nieder AM, Sved PD, Stein JP, Skinner DG, Soloway MS. Cystoprostatectomy and orthotopic ileal neobladder reconstruction for management of Bacille Calmette Guerininduced bladder contractures. Urology. 2005;65:909-912.
23. Briggs AH, Goeree R, Blackhouse G, O'Brien BJ. Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Making. 2002;22:290-308. (Pubitemid 34791317)
24. Feenstra TL, Hamberg-van Reenen HH, Hoogenveen RT, Rutten-van Molken MP. Cost-effectiveness of face-to-face smoking cessation interventions: a dynamic modeling study. Value Health. 2005;8:178-190.
25. Bank of Canada. Rates and Statistics. Inflation Calculator. Ottawa, Ontario Canada: Bank of Canada; 2006. Available at: http://www.bankofcanada.ca/ en/rates/inflation-calc.html 2006 Accessed on April 8, 2008.
26. Schiller J, Tilden D, Aristides M, et al. Retrospective cost analysis of gemcitabine in combination with cisplatin in non-small cell lung cancer compared to other combination therapies in Europe. Lung Cancer. 2004;43:101-112. (Pubitemid 38096299)
27. Roberts JT, von der Maase H, Sengelov L, et al. Long-term survival results of a randomized trial comparing gemcitabine/ cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer. Ann Oncol.2006;17(suppl 5):v118-v122. (Pubitemid 43985220)
28. Comella P, Frasci G, Panza N, et al. Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group. J Clin Oncol. 2000;18:1451-1457. (Pubitemid 30205390)
29. Schiller JH, Harrington D, Belani CP, et al. Comparison of 4 chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92-98. (Pubitemid 34438899)
30. Ministry of Health and Long-Term Care, Ontario Hospital Insurance Plan (OHIP). Schedule of Benefits. Ottawa, Ontario, Canada: Ministry of Health and Long-Term Care; 2005. Available at: http://www.health.gov.on.ca/english/ providers/ program/ohip/sob/physserv/physserv-mn.html 2005 Accessed on June 5, 2006.
31. Ministry of Health and Long-Term Care. Ontario Drug Benefit Formulary/Comparative Drug Index, 39th ed. Ottawa, Ontario, Canada: Ministry of Health and Long-Term Care; 2006. Available at: http://www.health.gov. on.ca/english/providers/ program/drugs/odbf-mn.html Accessed June 5, 2006.
32. Owens DK. Interpretation of cost-effectiveness analyses. J Gen Intern Med. 1998;13:716-717.
33. Coyle D, Oakley J. Estimating the expected value of partial perfect information: a review of methods. Eur J Health Econ. 2008;9:251-259. (Pubitemid 351962398)
34. Elting LS, Pettaway C, Bekele BN, et al. Correlation between annual volume of cystectomy, professional staffing, and outcomes: a statewide, population-based study. Cancer. 2005;104:975-984. (Pubitemid 41170225)
35. Chahal R, Sundaram SK, Iddenden R, Forman DF, Weston PM, Harrison SC. A study of the morbidity, mortality and long-term survival following radical cystectomy and radical radiotherapy in the treatment of invasive bladder cancer in Yorkshire. Eur Urol. 2003;43:246-257. (Pubitemid 36314236)
36. Bramkamp M, Radovanovic D, Erne P, Szucs TD. Determinants of costs and the length of stay in acute coronary syndromes: a real life analysis of more than 10,000 patients. Cardiovasc Drugs Ther. 2007;21:389-398. (Pubitemid 47598924)
37. Cooksley CD, Avritscher EB, Grossman HB, et al. Clinical model of cost of bladder cancer in the elderly. Urology. 2008;71:519-525.
38. Kulkarni JN, Gupta R. Recurrence and progression in stage T1G3 bladder tumour with intravesical Bacille Calmette-Guerin (Danish 1331 strain). BJU Int. 2002; 90:554-557.
39. Lotan Y, Roehrborn CG. Cost-effectiveness of a modified care protocol substituting bladder tumor markers for cystoscopy for the follow-up of patients with transitional cell carcinoma of the bladder: a decision analytical approach. J Urol. 2002;167:75-79. (Pubitemid 34024503)
40. Hong YM, Loughlin KR. Economic impact of tumor markers in bladder cancer surveillance. Urology. 2008;71: 131-135.
41. Lotan Y, Svatek RS, Sagalowsky AI. Should we screen for bladder cancer in a high-risk population? A cost per lifeyear saved analysis. Cancer. 2006;107:982-990. (Pubitemid 44291147)
42. Svatek RS, Sagalowsky AI, Lotan Y. Economic impact of screening for bladder cancer using bladder tumor markers: a decision analysis. Urol Oncol. 2006;24:338-343. (Pubitemid 43963410)
43. Racioppi M, Volpe A, Falabella R, et al. The cost of treatment and follow-up of bladder cancer in Italy. Arch Ital Urol Androl. 2007;79:111-117. (Pubitemid 350073481)
44. Konety BR, Allareddy V. Influence of post-cystectomy complications on cost and subsequent outcome. J Urol. 2007;177:280-287; discussion 287. (Pubitemid 44879457)
45. Marchetti A, Wang L, Magar R, et al. Management of patients with Bacilli Calmette-Guerin-refractory carcinoma in situ of the urinary bladder: cost implications of a clinical trial for valrubicin. Clin Ther. 2000;22:422-438. (Pubitemid 30304794)
46. Stenzl A, Hennenlotter J, Schilling D. Can we still afford bladder cancer? Curr Opin Urol.2008;18:488-492.
47. Solsona E, Iborra I, Rubio J, Casanova J, Almenar S. The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour. BJU Int. 2004;94:1258-1262. (Pubitemid 40052089)
48. Studer UE, Burkhard FC, Schumacher M, et al. Twenty years experience with an ileal orthotopic low pressure bladder substitute-lessons to be learned. J Urol. 2006;176: 161-166. (Pubitemid 43815402)
49. Stein JP, Dunn MD, Quek ML, Miranda G, Skinner DG. The orthotopic T pouch ileal neobladder: experience with 209 patients. J Urol. 2004;172:584-587. (Pubitemid 38900211)
50. Meyer JP, Drake B, Boorer J, Gillatt D, Persad R, Fawcett D. A 3-centre experience of orthotopic neobladder reconstruction after radical cystectomy: initial results. BJU Int. 2004;94:1317-1321. (Pubitemid 40052101)
51. Krahn MD, Zagorski B, LaPorte A, et al. Healthcare costs associated with prostate cancer: estimates from a population- based study. BJU Int. In press.